- Buyers of the $5.75 billion bonds have questioned the timing
- Bayer bonds slumped after the drug development setback
Bayer AG said it didn’t know the results of its blood-thinner drug trial, which was halted this week due to a lack of efficacy, before selling $5.75 billion of bonds to investors.
The company has faced questions from investors and analysts, who have asked whether it knew about the outcome of the study, which tested the anti-thrombotic drug asundexian, prior to the debt sale.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.